Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?

finance.yahoo.com/news/beaten-down-summit-therapeutics-stock-092300133.html

In This Article:
Key Points
-
Summit Therapeutics stock fell hard recently in response to disappointing clinical trial results.
-
Ivonescimab failed to produced a statistically significant overall survival benefit in the phase 3 Harmoni trial.
-
Ivonescimab has been approved by Chinese…

This story appeared on finance.yahoo.com, 2025-06-02 09:23:00.
The Entire Business World on a Single Page. Free to Use →